Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer.
Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer.
复制标题
欧洲癌症研究与治疗组织生活质量问卷-睾丸癌26针对睾丸癌患者的日本版验证研究。
作者：
Yamashita S;Suzukamo Y;Kakimoto K;Uemura M;Kishida T;Kawai K;Nakamura T;Goto T;Osawa T;Yamada S;Nishimura K;Nonomura N;Nishiyama H;Shiraishi T;Ukimura O;Ogawa O;Shinohara N;Ito A;Arai Y
ObjectiveValidation日文版的欧洲癌症研究与治疗组织生活质量问卷-睾丸癌26在讲日语的睾丸癌survivor.MethodsA共200名睾丸癌幸存者被招募在8个高容量的机构在日本。参与者完成了日本版的欧洲癌症研究和治疗组织生活质量问卷-睾丸癌26，欧洲癌症研究和治疗组织生活质量问卷-核心30和国际勃起功能指数15问卷。共有40名参与者在第一次回答后2周完成了问卷的重测。日本版本的心理测量学特性，包括重测信度，内部一致性和并行validity.ResultsThe响应的平均年龄为43岁（范围22-74岁），治疗后的平均时间为77个月（范围0-416个月）。除性功能外，各项目的回答率均较高，缺失值的百分比小于3.5%。对于重测信度，12个量表中有7个符合标准（组内相关0.70-0.86）。对于内部一致性，七个量表中有四个符合标准（Cronbach α 0.62-0.91）。对于同时有效性，欧洲癌症研究与治疗组织生活质量问卷-睾丸癌26的治疗副作用与欧洲癌症研究与治疗组织生活质量问卷-核心30的某些领域相关。欧洲癌症研究与治疗组织生活质量问卷-睾丸癌26的性别相关的分量表与一些国际勃起功能指数15 domains.ConclusionsThe心理测量属性的日本版相当于原来的欧洲癌症研究与治疗组织生活质量问卷-睾丸癌26的属性。欧洲癌症研究和治疗组织生活质量问卷-睾丸癌26问卷的日文版是评估睾丸癌患者健康相关生活质量的有用工具。
ObjectiveTo validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 in Japanese‐speaking testicular cancer survivors.MethodsA total of 200 testicular cancer survivors were recruited at eight high‐volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test–retest reliability, internal consistency and concurrent validity were evaluated.ResultsThe mean age at response was 43 years (range 22–74 years), and the mean period after treatment was 77 months (range 0–416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test–retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70–0.86). For internal consistency, four of seven scales met the criteria (Cronbach’s alpha 0.62–0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30. The sex‐related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains.ConclusionsThe psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 questionnaire is a useful tool to assess the health‐related quality of life of testicular cancer patients.